Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
European Journal of Cancer2017Vol. 82, pp. 56–65
Citations Over TimeTop 1% of 2017 papers
Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler, Andrea Forschner, Michael Constantin Kirchberger, Carmen Loquai, Markus Meißner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei‐Shamsabadi, Sebastian Haferkamp, Margit A. Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G. Schäd, C. Schmid-Tannwald, Julia K. Tietze, Thomas Eigentler, Carola Berking
Related Papers
- → Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab(2016)21 cited
- → Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma(2019)17 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)